Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Inclusion Criteria: * Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer * Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, or clear cell carcinoma (Pure or Mixed). * Have measurable disease * FRα-positive tumor expression as defined in the protocol * Have at least one "target lesion" to be used to assess response as defined by RECIST v1.1 * Patients must have received prior treatment with ≤ 3 prior lines of therapy for recurrent disease; hormonal agents are not considered a line of therapy; prior treatment with folate receptor-targeting investigational agents is not allowed * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Time from prior therapy: Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter; Radiotherapy: wide-field radiotherapy completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment * Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy * Patients must have adequate hematologic, liver and kidney function as defined in the protocol * Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at …